ES2871783T3 - Compuestos para el tratamiento de trastornos del metabolismo de las lipoproteínas - Google Patents

Compuestos para el tratamiento de trastornos del metabolismo de las lipoproteínas Download PDF

Info

Publication number
ES2871783T3
ES2871783T3 ES17776978T ES17776978T ES2871783T3 ES 2871783 T3 ES2871783 T3 ES 2871783T3 ES 17776978 T ES17776978 T ES 17776978T ES 17776978 T ES17776978 T ES 17776978T ES 2871783 T3 ES2871783 T3 ES 2871783T3
Authority
ES
Spain
Prior art keywords
pcsk9
compound
formula
group
rldl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17776978T
Other languages
English (en)
Spanish (es)
Inventor
Camilla Gustafsen
Søndergaard Madsen
Glerup Pedersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aarhus University
Original Assignee
Aarhus University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aarhus University filed Critical Aarhus University
Application granted granted Critical
Publication of ES2871783T3 publication Critical patent/ES2871783T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES17776978T 2016-09-20 2017-09-20 Compuestos para el tratamiento de trastornos del metabolismo de las lipoproteínas Active ES2871783T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201670733 2016-09-20
PCT/EP2017/073747 WO2018054959A1 (en) 2016-09-20 2017-09-20 Compounds for treatment of lipoprotein metabolism disorders

Publications (1)

Publication Number Publication Date
ES2871783T3 true ES2871783T3 (es) 2021-11-02

Family

ID=59974406

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17776978T Active ES2871783T3 (es) 2016-09-20 2017-09-20 Compuestos para el tratamiento de trastornos del metabolismo de las lipoproteínas

Country Status (9)

Country Link
US (2) US11173177B2 (enExample)
EP (1) EP3515455B1 (enExample)
JP (1) JP7046381B2 (enExample)
CN (1) CN110494145A (enExample)
AU (1) AU2017329799A1 (enExample)
CA (1) CA3035875A1 (enExample)
DK (1) DK3515455T3 (enExample)
ES (1) ES2871783T3 (enExample)
WO (1) WO2018054959A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3271405A1 (en) * 2015-03-20 2018-01-24 Aarhus Universitet Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
KR102137147B1 (ko) * 2018-07-16 2020-07-24 경희대학교 산학협력단 벤질 알파-d-갈락토피라노사이드 또는 (-)-세코이소라리시레시놀-9'-o-베타-d-글루코피라노사이드를 포함하는 당뇨병 예방 또는 치료용 조성물
SE543275C2 (en) * 2019-03-07 2020-11-10 Tx Medic Ab Treatment efficiency evaluation
WO2021122793A1 (en) * 2019-12-17 2021-06-24 Norinvent Ab Sulfated disaccharides as enhancers of transmucosal drug uptake
KR20230057410A (ko) 2020-08-25 2023-04-28 리제너론 파마슈티칼스 인코포레이티드 Pcsk9 및 ldlr 조절인자를 사용한 패혈증 치료
CN116854752B (zh) * 2022-03-28 2026-08-04 南开大学 肝素三糖结构化合物及其制药应用
CN116270507A (zh) * 2023-03-02 2023-06-23 青岛海洋生物医药研究院股份有限公司 一种含脂蛋白脂酶刺激剂的舌下含片及其制备方法和应用
CN119708089B (zh) * 2023-09-27 2026-06-26 南开大学 一种磺酸化三糖及其制备方法和治疗应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
WO1993007167A1 (en) 1991-10-04 1993-04-15 The Procter & Gamble Company Cholesterol lowering compounds and process for making them
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5366473A (en) 1992-08-18 1994-11-22 Ultrasonic Sensing And Monitoring Systems, Inc. Method and apparatus for applying vascular grafts
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
CA2117477C (en) 1992-12-11 2001-06-12 Peter S. Mezes Multivalent single chain antibodies
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
ES2584927T7 (es) * 2007-10-16 2020-11-05 Progen Pg500 Series Pty Ltd Derivados de oligosacáridos sulfatados novedosos
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
KR101293278B1 (ko) 2009-10-29 2013-08-09 주식회사 한독 신규 혈관누출 차단제
CN104169304A (zh) 2011-12-20 2014-11-26 阿达拉塔合伙有限公司 作为pcsk9抑制剂的单域抗体
WO2013148284A1 (en) 2012-03-29 2013-10-03 Genentech, Inc. Antibodies that bind to a pcsk9 cleavage site and methods of use
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
WO2013177536A2 (en) 2012-05-25 2013-11-28 Catabasis Pharmaceuticals, Inc. Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)
WO2014005224A1 (en) 2012-07-03 2014-01-09 Majambu Mbikay Quercetin-3-glucoside and uses thereof
US10188693B2 (en) * 2012-08-02 2019-01-29 Stealth Biotherapeutics Corp Methods for treatment of atherosclerosis
AU2014235430A1 (en) 2013-03-15 2015-09-24 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (PCSK9)
EP3197492A1 (en) * 2014-09-23 2017-08-02 Pfizer Inc Treatment with anti-pcsk9 antibodies
EP3271405A1 (en) * 2015-03-20 2018-01-24 Aarhus Universitet Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders

Also Published As

Publication number Publication date
CN110494145A (zh) 2019-11-22
EP3515455A1 (en) 2019-07-31
AU2017329799A1 (en) 2019-04-11
DK3515455T3 (da) 2021-07-05
WO2018054959A1 (en) 2018-03-29
US20220054530A1 (en) 2022-02-24
US20190275074A1 (en) 2019-09-12
US11173177B2 (en) 2021-11-16
EP3515455B1 (en) 2021-04-14
JP7046381B2 (ja) 2022-04-04
JP2019529402A (ja) 2019-10-17
CA3035875A1 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
JP7046381B2 (ja) リポタンパク質代謝障害の治療のための化合物
Chen et al. Calycosin reduces myocardial fibrosis and improves cardiac function in post-myocardial infarction mice by suppressing TGFBR1 signaling pathways
Lee et al. The use of low molecular weight heparin–pluronic nanogels to impede liver fibrosis by inhibition the TGF-β/Smad signaling pathway
Lin et al. The protective effect of hesperetin in osteoarthritis: an in vitro and in vivo study
Akasaki et al. Dysregulated FOXO transcription factors in articular cartilage in aging and osteoarthritis
ES2924479T3 (es) Composiciones para rejuvenecer las células madre del músculo esquelético
US9132123B2 (en) Combined therapy for cystic fibrosis
JP2010503710A5 (enExample)
Hossain et al. Ginsenoside-Rb1 prevents bone cartilage destruction through down-regulation of p-Akt, p-P38, and p-P65 signaling in rabbit
Gu et al. Curcumin analogue AI-44 alleviates MSU-induced gouty arthritis in mice via inhibiting cathepsin B-mediated NLRP3 inflammasome activation
US20170042964A1 (en) Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
KR101985719B1 (ko) 베타글루칸-펩타이드 복합체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물
Naidu et al. RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF-κB activation and down regulating inflammatory cytokines
CA2998455A1 (en) Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof
ES2862103T3 (es) Asociaciones farmacéuticas de agonistas de receptores de factor de crecimiento e inhibidores de proteínas de adhesión para la conversión de células neoplásicas en células no neoplásicas y usos de las mismas
EP1680104A1 (en) Composition for treatment of osteoarthritis containing apigenin as chindroregenerative agent
WO2019157085A2 (en) INHIBITION OF WNT/β-CATENIN SIGNALING IN THE TREATMENT OF OSTEOARTHRITIS
US10272133B2 (en) Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
Wu et al. Melittin alleviates osteoarthritis via mitophagy mediated by the AMPK/PINK1/Parkin Axis
US20130184330A1 (en) Compositions and methods for inducing cancer cell death
WO2017046229A1 (en) Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
Shrestha et al. Proteinuria Converts Hepatic Heparan Sulfate To Effective PCSK9 Binding Partner
Lin et al. Stabilization of β-catenin by 7, 8-Dihydroxyflavone protects against osteoblast ferroptosis and bone loss in type 2 diabetic osteoporosis
Tandon et al. Identification and Characterization of a Calcium Oxalate Crystal Growth Protien inhibitor form Human Rebal stone Matrix
Idris et al. Identification of novel biphenyl carboxylic acid derivatives as novel antiresorptive agents which do not impair PTH induced bone formation